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social life and expectations between women and men.
Deeper societal changes are needed to reduce the
inequities in pain experience between women and men.
PPN5
ASSESSING PATIENT SATISFACTION WITH
PHARMACOLOGICAL PAIN TREATMENT IN
AMBULATORY PRIMARY CARE PATIENTS
Baró E1, Casado AJ1, García-Cases C2, Clerch L2, Ribas S1
13D Health Research, Barcelona, Barcelona, Spain; 2Lácer, S. A,
Barcelona, Barcelona, Spain
OBJECTIVES: To develop a reliable, valid and sensitive
tool to assess satisfaction with pharmacological pain
treatment among primary care patients. METHODS:
Content sources for the initial version (IV) were biblio-
graphic review, focus groups with patients, and expert
opinion. IV was tested in a prospective study with ambu-
latory pain patients. Item-total statistics and exploratory
factor analysis (FA) were performed for item reduction.
The ﬁnal version (FV) was psychometrically assessed by:
internal consistency (Cronbach’s alpha—CA), test-retest
reliability in patients maintaining treatment (intraclass
correlation coefﬁcient ICC), convergent/discriminant
validity (SF-12 and pain intensity—VAS), construct valid-
ity (lineal multiple regression), extreme groups validity
for patients presenting pain relief (ROC curves) and
responsiveness in patients changing treatment (effect
size—ES). RESULTS: The IV was administered to 362
patients (58% women, age 51y, 48% suffering from
osteoarthritis). Four items were deleted from the IV
owing to a low item-scale homogeneity, leading-weight 
in FA and/or contribution to CA values. The ﬁnal FA
explained 70.2% of the variance. Four dimensions were
identiﬁed: adverse events (AE), speed-duration of effect,
functional beneﬁt and overall satisfaction. A total of
97.2% of patients full-completed the FV. CA for the
global score (GS) was 0.88 and over 0.80 for all dimen-
sions. ICC for GS was 0.73 and ranged from 0.59 (func-
tional beneﬁt) to 0.80 (AE). Correlations were low to
moderate with SF-12 (0.11–0.30) and moderate to good
with VAS (0.48 to 0.55, except AE, 0.20). Pain frequency,
intensity and relief were independently associated with
satisfaction GS, accounting for 43.5% of variance. Area
under the curve was 0.78 for GS and over 0.65 for all
dimensions (except AE, 0.57). ES were large for GS and
dimensions (0.8 to 2.5). CONCLUSIONS: This new 10-
item measure has proved to be reliable, valid and sensi-
tive to assess pharmacological pain treatment satisfaction
in primary care patients.
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CRITICAL PATHWAY STATUS: A COMPARISON
OF PATIENT OUTCOMES
Hanley KN, Peterman AH, Reynolds K, Caprini CA
Evanston Northwestern Health care, Evanston, IL, USA
OBJECTIVES: To compare patient reported outcomes of
pain and quality of life (QOL) between breast cancer
surgery patients. The analysis compared one patient
group that was on a critical pathway to a patient group
that was not on a critical pathway during their hospital
stay. METHODS: A quasi-experimental study of patients
discharged for breast cancer surgery at a community-
based teaching hospital. The analysis for this study
included 3 distinct patient-reported pain ratings 3–6 days
post-discharge: highest and lowest levels since discharge
and current level of pain at the time of assessment. Addi-
tionally, patients completed the Functional Assessment of
Cancer Therapy-Breast Subscale (FACT-B) six months
post-discharge. Data were collected via telephone inter-
view. RESULTS: Study groups were found to have similar
sociodemographic characteristics. There were no statisti-
cally signiﬁcant differences between the study groups for
the pain or QOL outcomes. Length of stay (LOS) was
found to be statistically signiﬁcant between the pathway
and non-pathway groups (p = 0.020). A total of 77.3%
of the pathway group and 76.7% of the non-pathway
reported pain ratings ≥3 when rating their highest level
of pain since discharge. CONCLUSIONS: Regardless of
pathway status, patients reported similar outcomes of
pain and QOL. The implementation of the pathway
helped formalize the care delivered at the institution.
While the ﬁndings illustrate consistent delivery of care
regardless of pathway status, they also indicate further
attention to pain management post-discharge is needed.
Over 75% of patients in both groups did not meet the
pathway standard when rating their highest level of pain.
The pathway can serve as an informative tool by identi-
fying areas for improvement. The data gathered can be
used as a baseline comparison measure once these areas
have been identiﬁed and changes implemented. Future
research should evaluate pathways and their impact on
patient care after a patient has been discharged from the
hospital.
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THE WILLINGNESS-TO-PAY APPROACH IN THE
COST-BENEFIT ANALYSIS: THE TREATMENT OF
PATIENTS AFFECTED FROM PAINFUL
PATHOLOGY
Colombo GL1, Caruggi M2, Muzio A1
1S.A.V.E. Economic eValuation Analyses Studies, Milano, Milan,
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OBJECTIVES: To measure the willingness-to-pay of
patients who suffer from benign and intense chronic pain
and to investigate the relationship with the social and
demographic characteristics of the sample and the stated
and perceived quality of life. METHODS: Data from a
research on a sample of 205 and 158 patients suffering
from intense and chronic pain will be discussed, as in the
questionnaire it was asked how much every patient would
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be disposed to pay to eliminate pain. The question pre-
viewed an alternative answer between 4 possibilities that
represent a range of values that were deﬁned a priori.
Contents: To estimate in a critical way the use of the WTP
method cost effectiveness analyses. In this case the WTP
is used as an indicator of the potential question of the
patients for a greater treatment of pain. Results about
WTP and the relations between the social and demo-
graphic features will be discussed. WTP will also be asso-
ciate to the expectations on the treatment of pain and the
quality of life level and expected utility, obtained by 
the SF-36 and EQ-5D questionnaires, before the start of
treatments and after the check of therapy. RESULTS: The
analysis has allowed to quantify in €126,53 the willing-
ness to pay in order to eliminate the intense pain in 24
hours and in €236,74 the mean of the willingness to pay
in order to eliminate the chronic pain in 30 days. CON-
CLUSION: Combined analyses of the WTP and the
quality of life (Eq-5d) has shown interesting relations
between the gravity of painful pathology and the will-
ingness to pay in order to eliminate it. Meaningful rela-
tions have recorded also between the WTP and the
different kinds of perceived pain and expectation in the
treatment of pain.
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SUSTAINED-RELEASE TRAMADOL IN CHRONIC
PAIN TREATMENT: EFFECTIVENESS AND
INFLUENCE ON QUALITY OF LIFE
López JS1, Barnés E1, Samper D2, Casals M3, Suárez A4
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OBJECTIVE: Assess effectiveness and health related
quality of life of sustained-release tramadol in chronic
pain treatment. METHODS: Prospective, multicenter and
observational study. Out-patients attending Spanish pain
units who initiate treatment with tramadol were
recruited. Anthropometric characteristics, type of pain,
intensity of pain scored on a visual analogical scale (VAS)
were registered. Lattinen test and score on a sleep quality
scale were recorded at the beginning of treatment.
Follow-up visits were performed after a week and a
month of treatment, when adverse events and treatment
variations were registered. SF-12 questionnaire was ful-
ﬁlled by patients at initiation and ﬁnal visits. RESULTS:
Out of 907 patients, 66.03% were women. A total of
52.9% patients affected with lumbalgia and 33.9% with
osteoarthritis. After a month of treatment all pain indi-
cators experimented a signiﬁcant decrease: VAS score
diminished from 7.3 ± 1.3 to 4.6 ± 2.6 (p < 0.05) and to
3.9 ± 2.4 (p < 0.05) at ﬁrst week and month respectively,
Lattinen score improved from 12.0 ± 2.6 to 9.3 ± 3.5 (p
< 0.05) and 7.7 ± 3.7 (p < 0.05) successively. Score on
sleep quality scale increased from 4.8 ± 2.6 to 5.2 ± 32
(p < 0.05) and 5.2 ± 3.9 (p < 0.05) along follow-up visits.
Rate compliance was 93.2% out of patients during the
month of study. Quality of life was mainly improved on
physical sphere (increase of 5.6 ± 9.6, p < 0.01). VAS
score, Lattinen test score, arthrosis or visceral pain,
regular exercise and normal weight accounted as a mean
predictive factors for physical quality of life. CONCLU-
SIONS: Sustained-release Tramadol showed to be effec-
tive on chronic pain at ﬁrst week of treatment. Treatment
effectiveness was reﬂected on a signiﬁcant improvement
on physical quality of life. Daily unique dosage may act
as an important factor for good treatment compliance.
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CHRONIC PAIN PATIENTS’ SATISFACTION AND
QUALITY OF LIFE WITH TRANSDERMAL
ANALGESIC MEDICATION
Anderson-Hillemacher A, Hastedt C
Gruenenthal GmbH, Aachen, Germany
OBJECTIVES: Main objective is the analysis of chronic
pain patients’ satisfaction with transdermal analgesic
medication and related quality of life. Satisfaction with
the application form is one aspect of patient satisfaction
that is not often examined. This study compares patient
satisfaction and quality of life with a buprenorphine
transdermal system (Transtec®) vs oral medication/tablet
(different substances). METHODS: Chronic pain patients
were documented in a post marketing surveillance. Of
these 160, mainly out-patients with chronic muscu-
loskeletal pain, were asked to participate in this investi-
gation additionally. They completed a battery with
quality of life scales (e.g. SF 36) and an additional, vali-
dated questionnaire about patient satisfaction with the
analgesic medication. Questionnaires were administered
at two measuring points: when still using tablets and 4–8
weeks later, after the change to the transdermal system
(patch). RESULTS: Quality of Life (e.g. SF 36) was gen-
erally very low among the sample. Especially physical
functioning and vitality were impaired by chronic disease
and chronic pain. The results of the patient satisfaction
questionnaire indicate, that patients were more satisﬁed
with transdermal analgesic medication than with tablets,
especially if they proﬁt from higher mobility/autonomy,
e.g. by being able to work again. Overall satisfaction with
the buprenorphine transdermal system was not only inﬂu-
enced by perceived impairment by pain and effectiveness
of the analgesic but also by mobility/autonomy, satis-
faction with quality of life and the doctor-patient-
relationship. CONCLUSIONS: Patient Satisfaction with
transdermal analgesic medication is more than Quality of
Life and pain relief. Although all three aspects inﬂuence
each other, it’s worth exploring them separately.
